Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative volunteer for the Breast Disease Site Committee.
Please join CCTG on April 10 from 11:00 to 12:00 pm EST for a virtual round table on strategies for improving equity and access in cancer clinical trials. We are honoured to bring together Dr. Don S. Dizon and Dr. Sara Moore to guide us in this conversation which will be moderated by Dr. Janet Dancey. The goal of this discussion is to help participants consider strategies for enhancing clinical trial diversity and making clinical trials more accessible to all populations that may benefit from them.
Now open the CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost) for men with unfavourable risk prostate cancer. SBRT is a non-invasive, high precision, less costly radiation technique that results in similar outcomes and tolerability to brachytherapy boost.
The results of the CX5/SHAPE clinical trial, published today in the New England Journal of Medicine (NEJM), conclude that a simple hysterectomy is a safe treatment option for women with low-risk early-stage cervical cancer. The Phase III international trial compared radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection.
